In this issue:
Lower vs. standard dose antithymocyte globulin for aplastic anaemia
First-line rabbit antithymocyte globulin for severe aplastic anaemia
Brentuximab vedotin for relapsed/ refractory HL
Brentuximab vedotin + AVD with involved-site RT in unfavourable HL
Impact of immunoparesis status on amyloidosis outcomes
Pomalidomide + dexamethasone for amyloidosis
Prognostic model for DLBCL
Baseline metabolic tumour volume predicts follicular lymphoma outcomes
Ferric carboxymaltose improves postoperative anaemia
Please login below to download this issue (PDF)